Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins

Attaphol Pawarode(University of Michigan), Maria R. Baer(University of Maryland, Baltimore), Stacy M. Fricke, Suneet Shukla(National Cancer Institute), Suresh V. Ambudkar(National Institutes of Health), Kieran L. O’Loughlin(Roswell Park Comprehensive Cancer Center), Elaine Pinder(Roswell Park Comprehensive Cancer Center), Hans Minderman(Roswell Park Comprehensive Cancer Center)
Cancer Chemotherapy and Pharmacology
October 9, 2006
10.1007/s00280-006-0357-8
Cited by 76

Related Papers

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
|The Lancet Oncology|2017|493
Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia
|Journal of Clinical Oncology|2012|408